Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cardinal Health Inc (CAH) vs CarMax, Inc (KMX) Price & Performance

Cardinal Health IncTrade
CarMax, IncTrade

Price performance (Past 24H)

Key statistics

Cardinal Health Inc vs CarMax, Inc — how do they compare? Cardinal Health Inc trades at $237.28 (market cap $55.88B), while CarMax, Inc trades at $58.34 (market cap $8.26B). The key difference: Cardinal Health Inc is far larger — about 6.8× CarMax, Inc's market cap, and Cardinal Health Inc pays a 0.86% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals.

CAHKMX
Market Cap
$55.88B$8.26B
Sector
HealthConsumer Cyclical
52-Week High
$240.26$62.17
52-Week Low
$146.04$30.88
Enterprise Value
$59.91B$26.77B
Dividend Yield
0.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cardinal Health Inc

Cardinal Health (CAH) trades at $236.87, down 0.13% on the day, near its 52-week high. The stock shows strong momentum with four consecutive quarterly EPS beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Technical indicators are bullish overall, with moving averages supporting upward trends. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%.

Outlook remains positive driven by robust pharmaceutical demand and optimistic FY2027 guidance. Key risks include high debt levels and thin profit margins. Analysts maintain a bullish consensus with a $266.43 price target, representing 12.5% upside. The stock presents a growth opportunity but requires monitoring of margin pressures and cash flow volatility.

CarMax, Inc

CarMax (KMX) trades at $58.20, showing modest near-term weakness with a 0.99% daily decline. The stock maintains a bullish technical stance with strong moving average support and trades near key support at $58. Fundamentally, the company reported Q1 2026 earnings beat with $0.34 EPS versus $0.23 expected, though revenue trends show slight contraction from $26.4B in 2025 to projected $26.3B in 2026. Recent positive developments include AI partnership enhancements and strong institutional recognition.

CarMax presents a mixed investment case with technical strength offset by fundamental challenges. The bullish moving average configuration and recent earnings beats provide near-term support, but declining revenue trends and thin 0.84% net margin limit upside potential. Key risks include ongoing fiduciary investigations and competitive pressure in the used car market. Analyst consensus remains cautious with 68.6% hold ratings and $53.09 price target below current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cardinal Health Inc

Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Read more on CAH

About CarMax, Inc

CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.

Read more on KMX